PURPOSE: As primary osseous metastasis is the main adverse prognostic factor in patients with Ewing tumours, a NOD/scid mouse model for human Ewing tumour metastases has been established to examine the mechanisms of metastasis. The aim of this study was to evaluate the feasibility of diagnostic molecular imaging by small animal PET in this mouse model. METHODS: Human Ewing tumour cells were transplanted into immune-deficient NOD/scid mice via s.c injection (n=17) or i.v. injection (n=17). The animals (mean weight 23.2 g) were studied 2-7 weeks after transplantation using a submillimetre resolution animal PET scanner. To assess glucose utilisation and bone metabolism, mice were scanned after intravenous injection of 9.6 MBq (mean) 2-[(18)F]fluoro-2-deoxy-D: -glucose (FDG) or 9.4 MBq (mean) [(18)F]fluoride. Whole-body PET images were analysed visually and semi-quantitatively [%ID/g, tumour to non-tumour ratio (T/NT)]. Foci of pathological uptake were identified with respect to the physiological organ uptake in corresponding regions. RESULTS: Subcutaneously transplanted Ewing tumours demonstrated a moderately increased glucose uptake (median %ID/g 2.5; median T/NT 2.2). After i.v. transplantation, the pattern of metastasis was similar to that in patients with metastases in lung, bone and soft tissue. These metastases showed an increased FDG uptake (median %ID/g 3.6; median T/NT 2.7). Osseous metastases were additionally visible on [(18)F]fluoride PET by virtue of decreased [(18)F]fluoride uptake (osteolysis; median %ID/g 8.4; median T/NT 0.59). Metastases were confirmed immunohistologically. CONCLUSION: Diagnostic molecular imaging of Ewing tumours and their small metastases in an in vivo NOD/scid mouse model is feasible using a submillimetre resolution PET scanner.
PURPOSE: As primary osseous metastasis is the main adverse prognostic factor in patients with Ewing tumours, a NOD/scid mouse model for human Ewing tumour metastases has been established to examine the mechanisms of metastasis. The aim of this study was to evaluate the feasibility of diagnostic molecular imaging by small animal PET in this mouse model. METHODS: Human Ewing tumour cells were transplanted into immune-deficient NOD/scid mice via s.c injection (n=17) or i.v. injection (n=17). The animals (mean weight 23.2 g) were studied 2-7 weeks after transplantation using a submillimetre resolution animal PET scanner. To assess glucose utilisation and bone metabolism, mice were scanned after intravenous injection of 9.6 MBq (mean) 2-[(18)F]fluoro-2-deoxy-D: -glucose (FDG) or 9.4 MBq (mean) [(18)F]fluoride. Whole-body PET images were analysed visually and semi-quantitatively [%ID/g, tumour to non-tumour ratio (T/NT)]. Foci of pathological uptake were identified with respect to the physiological organ uptake in corresponding regions. RESULTS: Subcutaneously transplanted Ewing tumours demonstrated a moderately increased glucose uptake (median %ID/g 2.5; median T/NT 2.2). After i.v. transplantation, the pattern of metastasis was similar to that in patients with metastases in lung, bone and soft tissue. These metastases showed an increased FDG uptake (median %ID/g 3.6; median T/NT 2.7). Osseous metastases were additionally visible on [(18)F]fluoride PET by virtue of decreased [(18)F]fluoride uptake (osteolysis; median %ID/g 8.4; median T/NT 0.59). Metastases were confirmed immunohistologically. CONCLUSION: Diagnostic molecular imaging of Ewing tumours and their small metastases in an in vivo NOD/scid mouse model is feasible using a submillimetre resolution PET scanner.
Authors: M Paulussen; S Ahrens; A W Craft; J Dunst; B Fröhlich; S Jabar; C Rübe; W Winkelmann; S Wissing; A Zoubek; H Jürgens Journal: J Clin Oncol Date: 1998-09 Impact factor: 44.544
Authors: M Paulussen; S Ahrens; S Burdach; A Craft; B Dockhorn-Dworniczak; J Dunst; B Fröhlich; W Winkelmann; A Zoubek; H Jürgens Journal: Ann Oncol Date: 1998-03 Impact factor: 32.976
Authors: Klaus P Schäfers; Andrew J Reader; Michael Kriens; Christof Knoess; Otmar Schober; Michael Schäfers Journal: J Nucl Med Date: 2005-06 Impact factor: 10.057
Authors: J Vormoor; G Baersch; S Decker; M Hotfilder; K L Schäfer; L Pelken; C Rübe; F Van Valen; H Jürgens; B Dockhorn-Dworniczak Journal: Pediatr Res Date: 2001-03 Impact factor: 3.756
Authors: O Delattre; J Zucman; T Melot; X S Garau; J M Zucker; G M Lenoir; P F Ambros; D Sheer; C Turc-Carel; T J Triche Journal: N Engl J Med Date: 1994-08-04 Impact factor: 91.245
Authors: Sung-Hyeok Hong; Jason U Tilan; Susana Galli; Rachel Acree; Katherine Connors; Akanksha Mahajan; Larissa Wietlisbach; Taylor Polk; Ewa Izycka-Swieszewska; Yi-Chien Lee; Luciane R Cavalli; Olga C Rodriguez; Chris Albanese; Joanna B Kitlinska Journal: J Vis Exp Date: 2016-12-09 Impact factor: 1.355
Authors: Haixiang Liang; Shen-Ying Ma; Khalid Mohammad; Theresa A Guise; Gary Balian; Francis H Shen Journal: Spine (Phila Pa 1976) Date: 2011-04-01 Impact factor: 3.468
Authors: Jeannine Missbach-Guentner; Christian Dullin; Marta Zientkowska; Melanie Domeyer-Missbach; Sarah Kimmina; Silvia Obenauer; Fritz Kauer; Walter Stühmer; Eckhardt Grabbe; Wolfgang F Vogel; Frauke Alves Journal: Neoplasia Date: 2007-09 Impact factor: 5.715
Authors: Britta Vormoor; Henrike K Knizia; Michael A Batey; Gilberto S Almeida; Ian Wilson; Petra Dildey; Abhishek Sharma; Helen Blair; I Geoff Hide; Olaf Heidenreich; Josef Vormoor; Ross J Maxwell; Chris M Bacon Journal: PLoS One Date: 2014-01-07 Impact factor: 3.240